Gene therapy and coronary artery bypass grafting: current perspectives.

The early success of coronary artery bypass grafting (CABG) is limited by disappointing long-term patency rates of autologous saphenous vein grafts. Because current pharmacological interventions have only limited impact on vein graft patency rates, there remains a clear clinical need for effective a...

ver descrição completa

Detalhes bibliográficos
Main Authors: George, S, Channon, K, Baker, A
Formato: Journal article
Idioma:English
Publicado em: 2006
_version_ 1826270419138641920
author George, S
Channon, K
Baker, A
author_facet George, S
Channon, K
Baker, A
author_sort George, S
collection OXFORD
description The early success of coronary artery bypass grafting (CABG) is limited by disappointing long-term patency rates of autologous saphenous vein grafts. Because current pharmacological interventions have only limited impact on vein graft patency rates, there remains a clear clinical need for effective agents to prevent failure of vein grafts in the long term. Gene therapy in vein grafts has great potential as gene delivery can be achieved ex vivo at the time of cardiac surgery, allowing transgene expression to occur rapidly post-grafting within the acute phase of vein graft remodelling. A variety of therapeutic strategies have been tested in a range of preclinical models, although to date, these have not advanced to Inhuman trials, except in the setting of adjunctive angiogenesis for improved revascularization (phase 1). Clinical translation is warranted to investigate the potential of gene therapy to improve CABG patency rates in the long term.
first_indexed 2024-03-06T21:40:32Z
format Journal article
id oxford-uuid:47c74730-d80e-451a-98a5-462083db87ba
institution University of Oxford
language English
last_indexed 2024-03-06T21:40:32Z
publishDate 2006
record_format dspace
spelling oxford-uuid:47c74730-d80e-451a-98a5-462083db87ba2022-03-26T15:21:56ZGene therapy and coronary artery bypass grafting: current perspectives.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:47c74730-d80e-451a-98a5-462083db87baEnglishSymplectic Elements at Oxford2006George, SChannon, KBaker, AThe early success of coronary artery bypass grafting (CABG) is limited by disappointing long-term patency rates of autologous saphenous vein grafts. Because current pharmacological interventions have only limited impact on vein graft patency rates, there remains a clear clinical need for effective agents to prevent failure of vein grafts in the long term. Gene therapy in vein grafts has great potential as gene delivery can be achieved ex vivo at the time of cardiac surgery, allowing transgene expression to occur rapidly post-grafting within the acute phase of vein graft remodelling. A variety of therapeutic strategies have been tested in a range of preclinical models, although to date, these have not advanced to Inhuman trials, except in the setting of adjunctive angiogenesis for improved revascularization (phase 1). Clinical translation is warranted to investigate the potential of gene therapy to improve CABG patency rates in the long term.
spellingShingle George, S
Channon, K
Baker, A
Gene therapy and coronary artery bypass grafting: current perspectives.
title Gene therapy and coronary artery bypass grafting: current perspectives.
title_full Gene therapy and coronary artery bypass grafting: current perspectives.
title_fullStr Gene therapy and coronary artery bypass grafting: current perspectives.
title_full_unstemmed Gene therapy and coronary artery bypass grafting: current perspectives.
title_short Gene therapy and coronary artery bypass grafting: current perspectives.
title_sort gene therapy and coronary artery bypass grafting current perspectives
work_keys_str_mv AT georges genetherapyandcoronaryarterybypassgraftingcurrentperspectives
AT channonk genetherapyandcoronaryarterybypassgraftingcurrentperspectives
AT bakera genetherapyandcoronaryarterybypassgraftingcurrentperspectives